In a period where the proportion of culture confirmed cases in the UK has been steadily declining, diagnosis by PCR has been used to increase the number of confirmed cases and provide additional epidemiological data. This report presents a comparative evaluation of the fluorogenic probe-based 5P exonuclease assay (Taqman) using the Perkin-Elmer Applied Biosystems automated sequence detection system 7700 with previously reported polymerase chain reaction enzyme-linked immunosorbent (PCR ELISA) assays for the detection of meningococcal DNA in CSF, plasma and serum samples. Taqman assays developed were based on the detection of a meningococcal capsular transfer gene (ctrA), the insertion sequence IS1106 and the sialytransferase gene (siaD) for serogroup B and C determination and compared with similar assays in a PCR ELISA format. The Taqman ctrA assay was specific for Neisseria meningitidis, however the IS1106 assay gave false positive reactions with a number of non-meningococcal isolates. Sensitivity of the Taqman ctrA, IS1106 and siaD assays testing samples from culture-confirmed cases were 64, 69 and 50%, respectively, compared with 26, 67 and 43% for the corresponding PCR ELISA assays. Improvements to the DNA extraction procedure has increased the sensitivity to 93 and 91% for the TaqMan1 ctrA and siaD assays, respectively, compared to culture confirmed cases. Since the introduction of Taqman PCR a 56% increase in laboratory confirmed cases of meningococcal disease has been observed compared to culture only confirmed cases. The developed Taqman assays for the diagnosis of meningococcal disease enables a high throughput, rapid turnaround of samples with considerable reduced risk of contamination. ß
Introduction
The discrepancy between totals of meningococcal disease cases noti¢ed to the O¤ce of National Statistics for England and Wales, which includes clinical diagnosis alone and culture-proven meningococcal disease cases has increased in recent years [1] . This observation is due in part to the increasing use of pre-admission antibiotics and the greater circumspection about performing lumbar puncture. In response, the Public Health Laboratory Services (PHLS) Meningococcal Reference Unit (MRU) based at Withington Hospital, Manchester, UK introduced in 1992 serological assays that provide useful but retrospective evidence of meningococcal infection [1] . Non-culture polymerase chain reaction (PCR) assays have been described that can amplify meningococcal sequences direct from clinical samples [2^10], with some assays providing additional information about epidemiological markers such as the serogroup [2] , serotype [10] and serosubtype [9] .
Developments of assays in a PCR enzyme-linked immunosorbent assay (ELISA) format using internal oligonucleotide probes have improved sensitivity and speci¢city as well as allowing more rapid processing of samples in a microtitre plate format [2, 3, 10] . The development of PCR ELISA enabled the MRU to provide a non-culture service for the laboratory con¢rmation of meningococcal infection. However, the post PCR processing involved is lengthy and despite the inclusion of uracyl-N-glycosylase (UNG) manipulation of PCR products provides a potential source of contamination. Following the introduction of PCR testing as a national reference service for meningococcal case con¢rmation in 1995^1996 the demand in terms of numbers of samples submitted rapidly became overwhelming. With the level of throughput it became impossible to maintain the expected turnaround times using the PCR ELISA format. The Perkin-Elmer Applied Biosystems (PE-ABI) 7700 automated PCR platform employing Taqman chemistry was evaluated as a solution to this problem. The ABI sequence detection system employs £uorescence-based closed tube format that eliminates post PCR processing and provides accurate real-time quantitative PCR. Taqman assays have been described for the detection of several pathogenic organisms including hepatitis C [11, 12] , Salmonella spp. [13] , Listeria monocytogenes [14] toxigenic Escherichia coli [15] and Mycobacterium tuberculosis [16] . The Taqman assay utilises a dual-labelled £uorescent probe, the 5P end of which is labelled with one of several reporter dyes such as FAM (6, carboxy£uores-cein) and the 3P end with the £uorescent dye TAMRA (6, carboxy-tetramethylrhodamine) [17^20]. The spatial proximity to the reporter dye of the probe quenches the £uo-rescent emission. During ampli¢cation, the probe hybridises to the target sequence bound by the primers and is subsequently digested by the 5P exonuclease activity of Taq DNA polymerase during primer extension releasing the reporter dye resulting in a relative increase in £uorescent signal. Automated monitoring of the £uorescent signal is possible using the PE-ABI 7700 sequence detection system during thermal cycling. Thus, no post PCR-processing of ampli¢ed products is necessary. The monitored reporter signal for a reaction is identi¢ed as positive when the £uo-rescent signal exceeds a background threshold level. Ampli¢cation at this point is exponential and has been shown to be the most reliable approach to quanti¢cation of input nucleic acid [17, 18] .
This study reports the evaluation of the £uorogenic 5P nuclease assay (Taqman) for the detection of Neisseria meningitidis DNA from whole blood, plasma, serum and cerebrospinal £uid (CSF).
Methods
2.1. DNA extraction 2.1.1. Bacterial strains N. meningitidis isolates used were obtained from the MRU culture collection. Meningococcal serogrouping and serotyping were carried out as previously described [21, 22] . Other Neisserial species were obtained from the National Collection of Type Cultures (PHLS, Colindale, London, UK). Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus and Haemophilus in£uenzae cultures used were clinical isolates. DNA was extracted from overnight cultures grown on blood agar at 37³C in 5% CO 2 . Cultures were suspended in water and adjusted to approximately 2000 cfu 100 Wl 31 . Gram-negative bacteria were boiled for 15 min and centrifuged for 10 min at 12 000Ug. The supernatant was used as a PCR template and inoculated into the PCR reaction mix. Gram-positive bacterial DNA was extracted by adding 100 Wl of bacterial suspension to 1 ml of DNAzol1 solution (Life Technologies, Glasgow, UK), which was then vortexed and incubated for 10 min at room temperature. DNA was precipitated by adding 0.5 ml ethanol and centrifuging for 10 min at 12 000Ug. The pellet was washed with 1 ml of ethanol and ¢nally resuspended in 50 Wl sterile water.
The speci¢city of the Taqman ctrA and IS1106 assays was assessed by amplifying extracted DNA from other 
Clinical samples
Specimens of CSF, serum and plasma from culture proven and suspected meningococcal infection, were referred to the MRU from microbiology laboratories throughout England and Wales. Culture was attempted for all CSF samples by the referring laboratory. Samples were extracted as follows, CSF samples (50 Wl) were heated for 10 min at 100³C and centrifuged at 12 000Ug for 10 min. Serum or plasma (50 Wl) was mixed with 50 Wl of 1UPCR bu¡er (Life Technologies), heated at 100³C and centrifuged at 12 000Ug for 10 min. Supernatants from boiled extracts were used directly in PCR reaction mixes.
A subsequent evaluation of whole blood extractions was carried out using the Gentra DNA extraction kit (Flowgen, Lich¢eld, UK). A total of 216 consecutive EDTA blood samples from cases of meningococcal disease con¢rmed by blood culture were extracted and tested by TaqMan1 ctrA and siaD B and C assays. EDTA whole blood samples (200 Wl) were extracted using Gentra DNA extraction columns according to the manufacturer's instructions.
Primers and probes
Oligonucleotide primers and probes were used to detect the IS1106, ctrA and siaD gene sequences in PCR ELISA and Taqman assays are shown in Table 1 . Primers and probes used for the Taqman assays were synthesised by PE-ABI (Warrington, UK) and were designed using Primer Express software package (PE-ABI). Taqman probes were synthesised with the reporter dye FAM covalently linked to the 5P ends and the quencher dye TAMRA at the 3Pends which were phosphorylated to prevent probe extension.
PCR ELISA

DNA ampli¢cation
Aliquots (5 Wl) of extracted samples were added to a 45-Wl volume of PCR reaction mix comprising of 2 units of Taq DNA polymerase (Life Technologies, Glasgow, UK), 2 mM MgCl 2 , 5 Wl of 10Ubu¡er, 0.2 WM of each primer, 200 WM dATP, dGTP, dCTP, 50 WM dTTP, 150 WM dUTP, 10 WM digoxigenin-11-dUTP and 2 units of UNG (Boehringer Mannheim, Lewes, UK). Reaction mixes were incubated at 40³C for 10 min followed by 95³C for 10 min. Thermal cycling was carried out using an MJ PTC 200 thermal cycler (GRI, Braintree, UK) and cycling conditions were as follows : IS1106 assay (94³C for 25 s, 63³C for 40 s, 72³C for 60 s), ctrA assay, (94³C for 25 s, 56³C for 30 s, 72³C for 30 s) and for siaD B and siaD C assays (94³C for 60 s, 55³C for 40 s, 72³C for 60 s). Cycles were repeated 40 times for all assays with a ¢nal extension step of 5 min at 72³C.
ELISA detection
This was carried out according to the manufacturer's instructions (Boehringer Mannheim, Lewes, UK). Digoxigenin-labelled PCR products were hybridised in solution to sequence speci¢c biotin-labelled probes. Hybridised probes were immobilised on to streptavidin coated plates and subsequently detected by anti-digoxigenin peroxidase conjugate and the substrate ABTS. Optical density values at 450 nm were recorded. For each assay, negative plasma extraction controls were included after every ¢fth sample. Plasma containing 2000 cfu 100 Wl 31 of a cultured isolate of N. meningitidis was included in every test as an extraction control. The cut-o¡ was de¢ned as twice the mean of the negative controls.
Ampli¢cation using the PE-ABI 7700 sequence
detection system A volume of 2 Wl of extracted samples was added to 23 Wl of PCR reaction mix prepared from Taqman Core Reagent kit (PE-ABI) which comprised 0.12 units of Amplitaq Gold, 6 mM MgCl 2 , 200 WM of each of dATP, dCTP, dGTP and dUTP, 0.25 units of uracil-N-glycosylase, 200 WM of each of two primers and 100 WM of FAMlabelled probe. DNA ampli¢cation was carried out on the PE-ABI 7700 sequence detection system by heating at 50³C for 5 min, 95³C for 10 min followed by 45 cycles of a two-stage temperature pro¢le of 95³C for 15 s and 60³C for 1 min. Data points collected following primer extension were analysed at the end of thermal cycling. A threshold value is determined as 10 S.D. above the mean of the background £uorescence emission for all wells between cycle 1 and 15. The cycle number at which the £uo-rescence signal from a positive sample crosses this threshold is recorded.
Detection of PCR inhibitors
The PE-ABI exogenous internal control was used to determine if PCR inhibitors were present in the DNA extracts. Reagents are provided as a prepared kit which can be added to the TaqMan1 reaction mix described above. The kit contains control target DNA, a VIC1 £uores-cently labelled probe and appropriate primers. Concentration of the primers is reduced to prevent competition with the sample target DNA for PCR reaction components. Analysis of the ampli¢ed internal control was carried out using the TaqMan1 dedicated software which can resolve the FAM £urophore used to detect meningococcal PCR product and the VIC1 £uorophore for detection of the internal control PCR product.
An assessment of the presence of PCR inhibitors was carried out by amplifying 94 consecutive samples extracted by Gentra and by boiling using the TaqMan1 ctrA assay.
Generation of a quantitative standard
The PCR product generated from primers amplifying part of the ctrA gene was cloned using the Invitrogen TOPO (RpD systems Oxford, UK) cloning system. From a selected plasmid containing the cloned ctrA PCR product a puri¢ed plasmid preparation was obtained (Pureprep Kit, Pharmacia, Milton Keynes, UK). The optical density of the plasmid preparation was determined spectrophotometrically (GeneQuant, Pharmacia) and the DNA concentration calculated. Titration of this standard was used to determine the sensitivity of the ctrA assay by measuring the limit of detection.
Results
Speci¢city of IS1106 and ctrA PCR ELISA and Taqman assays
Isolates of N. meningitidis were selected on the basis of genotypic and phenotypic diversity. Other Neisserial species and meningitis causing pathogenic bacteria were tested by both IS1106 and ctrA Taqman assays. The PCR ELISA and Taqman IS1106 assays detected all the meningococcal isolates, however, two of the ten S. pneumoniae isolates, one of the ¢ve M. catarrhalis isolates and seven of the ten N. lactamica isolates were also ampli¢ed by the Taqman assay ( Table 2 ). The PCR ELISA and Taqman ctrA assays were negative for all non-meningococcal isolates tested. All serogroup B, C, Y and W135 meningococcal isolates were positive, however, the nonsialic acid containing capsular serogroup organisms A, X, Z and 29E were not detected because of nucleotide sequence variation within the 5P end of the ctrA gene [23] .
Speci¢city of the serogroup B and C siaD Taqman assay
Serogroup B and C meningococci of a diverse range of serotypes and serosubtypes were tested. As reported for equivalent PCR ELISA assays [2] , the Taqman siaD B assay detected exclusively serogroup B meningococci and the siaD C assay selectively identi¢ed only serogroup C meningococci. All other serogroups were negative by both siaD B and C assays.
Detection limit of Taqman assays
Tenfold dilutions of meningococci were prepared in pooled CSF plasma and serum negative for meningococcal DNA by PCR. From viable counts at each dilution, all four Taqman assays were able to detect less than one viable organism. In addition, titration of the cloned ctrA PCR product showed the Taqman assay to have a detection limit of two plasmid copies. 
Genbank accession codes for ctrA, IS1106, siaD B and siaD C are M57677, Z11857, M95053 and U75650, respectively. Probe 5P-3P is 5P biotin-labelled for PCR ELISA and 5P FAM-labelled for Taqman probes. Nucleotide positions are shown in brackets
Comparative sensitivity of PCR ELISA and Taqman assays with clinical samples
Clinical specimens (N = 44), including CSF, plasma and serum samples from patients with suspected meningococcal disease positive by both IS1106 and ctrA PCR ELISA assays were also positive by the Taqman ctrA assay, however only 41 (93%) were positive by the Taqman IS1106 assay. Of the 32 selected clinical samples that were IS1106 PCR ELISA positive and ctrA PCR ELISA negative, the Taqman IS1106 assay detected only 19 (59%) and the Taqman ctrA assay detected 29 (91%) ( Table 3) .
Comparative sensitivities for the PCR ELISA and Taqman assays with samples from culture con¢rmed cases showed an improved sensitivity for all four Taqman assays (Table 4) . Of 42 samples including CSF and serum or plasma samples tested by the Taqman assay, 29 (69%) were positive by the IS1106, 27 (64%) were positive by the ctrA assay and 21 (50%) were positive in either the siaD B or C assays compared with 28 (67%), 11 (26%), 18 (43%) positive by the PCR ELISA IS1106, ctrA and siaD B or C assays respectively. The 21 samples for which a serogroup was determined by Taqman represented 72% and 78% of Taqman IS1106 and ctrA positive samples respectively, and for the PCR ELISA the 18 serogroup positive samples represented 64% of the IS1106 positives. The ctrA PCR ELISA was less sensitive than the siaD assays detecting only 26% of the culture con¢rmed cases. All serogroup determinations by Taqman assay were also positive by the ctrA or IS1106, or both. PCR ELISA serogroup results were concordant with the Taqman assays.
The sensitivity of the Gentra extracted whole blood samples was compared with blood culture con¢rmed cases, and of 216 samples tested 201 (93%) were positive by TaqMan1 ctrA and 196 (91%) were positive in either the siaD B or C assays.
The 94 samples ampli¢ed with the TaqMan1 exogenous internal control showed no PCR inhibitors were present in either the boiled or Gentra extracts.
Impact on sample processing
A maximum of 50 samples could be processed in a working day using the PCR ELISA system taking approximately seven hours to complete. Using the ABI 7700 automated platform with a 96-well plate format it was feasible to process 200 samples per day, representing a four fold increase in throughput compared to the PCR ELISA format. Turnaround times were also reduced with same day results available for the screening assay and serogroup results available the following morning. In addition, identical thermocycling conditions for all Taqman assays allowed both ctrA and siaD assays to be run in the same plate.
Discussion
The development of PCR assays for the non-culture detection of meningococcal DNA has enabled con¢rma-tion of cases, where in particular, early antibiotic treatment precludes detection by culture. In addition the detection of meningococcal DNA from peripheral blood by PCR [2, 3, 6, 10] encourages clinicians to submit an easily accessible sample without the discomfort and risks associated with lumbar puncture. The introduction of PCR assays for the non-culture con¢rmation of meningococcal infection has markedly increased the number of con¢rmed cases. Analysis of data from the MRU showed that an additional 543 cases were identi¢ed by PCR alone between July 1996 and June 1997 which represented a proportional increase of 35% of the number of culture con¢rmed cases [24] . For 1998 an additional 871 cases have been con¢rmed by PCR alone from a total of 2445 laboratory con¢rmed cases, which represents an increase of 56% of the culture con¢rmed cases and 36% of the total number.
Speci¢city of the Taqman ctrA assay was comparable with the PCR ELISA ctrA assay, but showed an increased sensitivity most likely due to improved primer design. Sensitivity of the Taqman ctrA was comparable to the PCR ELISA IS1106 assay and titration of the cloned ctrA product in the Taqman assay was close to the theoretical limit with reproducible detection of two plasmid copies. The ctrA Taqman assay, however does not amplify serogroup A, X, 29E, Z, and H meningococci due to sequence var- iation between sialic and non-sialic acid containing serogroups [23] . This does not present a problem in the UK where serogroup B and C infection account for 939 5% of all cases in the UK [1] . The IS1106 Taqman assay performed less well and was less sensitive than the equivalent PCR ELISA assay. Speci¢city also appeared to be compromised in this assay which gave reactions with S. pneumoniae, M. catarrhalis and N. lactamica isolates. Transposable insertion elements are attractive targets for PCR assays since they are present as multiple copies in the genome, however the inherent genetic mobility results in their spread to other organisms [25, 26] . This therefore reduces the diagnostic utility of the IS1106 as a target for con¢rmation of menigococcal disease. The improved sensitivity of the meningococcal speci¢c ctrA PCR provides a more speci¢c alternative to the IS1106 as a target for con¢rmation of meningococcal infection.
The sensitivity of all PCR assays tested compared to culture con¢rmed cases was at best 69% (Table 4) , however, CSF was not always available for testing and of 13 PCR negative samples ¢ve plasma samples were examined where the isolate was cultured from CSF. The sensitivity of CSF samples may also be compromised as PCR examination is usually performed from centrifuged supernatant CSF samples previously examined by microscopy and culture by the referring laboratory. The Taqman siaD B and C assays were speci¢c for the respective sequence and more sensitive than their PCR ELISA equivalent assays. In both assay formats, the siaD B and C assays were less sensitive than the corresponding ctrA and IS1106 assays and may re£ect constraints on available sequence for discriminatory primer design. Substances inhibitory to PCR ampli¢cation can result in false negative results, however, both boiled and Gentra-extracted samples were shown not to contain inhibitors. Evaluation of the Gentra whole blood extracted samples showed a marked improvement in sensitivity (93%) when compared to blood culture con¢rmed cases. Di¡erences in the sensitivity between the two extraction methods were therefore due to di¡erences in the e¤ciency of the procedures. The aim of this evaluation was however to compare the performance of the PCR ELISA and TaqMan1 platforms which was independent of the e¤ciencies of the DNA extraction procedure.
The determination of serogroup provides a valuable epidemiological marker for identi¢cation and management of both sporadic cases and outbreaks enabling con¢rma-tion of outbreaks and appropriate vaccination. Samples from culture con¢rmed cases of meningococcal disease tested by all four Taqman assays were more sensitive than their corresponding PCR ELISA assays and a high proportion of positives (78% of ctrA positives) were positive by Taqman serogroup siaD B and C assays.
Fluorescence-based Taqman chemistry combined with the PE-ABI 7700 was shown to provide a robust assay format. Standardised commercial reagents together with the 96-well format allows reproducible, high throughput of samples with assay times of 2 h for combined ampli¢-cation and detection. In contrast to the PCR ELISA where sample processing takes 7^8 h, a four-fold greater throughput using the PE-ABI 7700 Taqman system can be achieved. The potential for high throughput of this system therefore allows a cost e¡ective centralised approach to diagnostic PCR testing which justi¢es the initial capital outlay.
As a result of this evaluation the Taqman ctrA assay has been adopted as a single screening test followed by determination of serogroup by siaD B and C assays on all positive samples. Currently more than 12 000 samples are being examined annually with over half this total received in four months from December through March. Use of the Taqman system has enabled a same day screening and serogroup determination for con¢rmation of meningococcal disease by PCR to be made available as a national reference service for patients throughout England and Wales.
Real-time PCR provides an accurate and reproducible method for quanti¢cation by PCR [17, 18] . The Taqman ctrA quantitative PCR data will be used in future work to assess the relationship between bacterial load and clinical outcome, which may provide important information regarding patient management.
